Sprites
Mein FinanzNachrichtenJetzt AnmeldenPasswort vergessen?
Montag, 28.05.2012Börsentäglich über 11.000 News von 416 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

DISCOVERY LABORATORIES INC

WKN: A1H5H4  ISIN: US2546684034  Ticker-Symbol: DYBN 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DISCOVERY LABORATORIES INC Chart 1 Jahr
1-Woche-Intraday-Chart
DISCOVERY LABORATORIES INC 1-Woche-Intraday-Chart

Aktuelle News zur DISCOVERY LABORATORIES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
21.05. 4
11.05. 7
04.05. 10
03.05. 18
WARRINGTON, Pa., May 3, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Reports First Quarter 2012 Financial Results
27.04. 1
23.04. 45
NEW YORK, NY -- (Marketwire) -- 04/23/12 -- Mergers and Acquisitions have been a hot topic in in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations...
Mehr lesen zu:
Large Pharmaceuticals Look to Smaller Biotech Companies to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Discovery Laboratories, Inc. and MannKind Corp.
21.03. 9
07.03. 46
WARRINGTON, Pa., March 7, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will...
Mehr lesen zu:
Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant)
06.03. 2
06.03. 4
06.03. 58
WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) for Prevention of Respiratory Distress Syndrome
08.02. -
08.02. 3
08.02. 38
WARRINGTON, Pa., Feb. 8, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Signs Manufacturing Agreement for AFECTAIR®
02.02. 33
WARRINGTON, Pa., Feb.2, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Cleared to Market AFECTAIR in U.S.
15 Nachrichten in den letzten 6 Monaten